Urinary bladder cancer (UBC) is a prevalent malignancy worldwide, exhibiting high recurrence rates and significant morbidity and mortality. Traditional diagnostic and prognostic methods often fall short in providing the precision required for effective patient stratification and personalized treatment. Genomic and transcriptomic studies have revolutionized our understanding of UBC by unveiling molecular alterations that drive tumor initiation, progression, and therapeutic response. This systematic review explores the role and application of genomic and transcriptomic analyses in the diagnostics and survival prediction of non-invasive and invasive UBC. We conducted a comprehensive literature search in MEDLINE, Web of Science, and Scopus up to October 2023, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our search yielded 1,256 records (412 in MEDLINE, 378 in Web of Science, and 466 in Scopus), and 356 duplicates were removed. Our findings highlight key mechanisms of action, including mutations in FGFR3, TP53, and RB1 genes, and alterations in pathways such as PI3K/AKT/mTOR and MAPK/ERK, which are pivotal in UBC pathogenesis. Recent research advances, including liquid biopsies and single-cell sequencing, offer promising non-invasive diagnostic tools and deeper insights into tumor heterogeneity. This review underscores the critical importance of integrating genomic and transcriptomic data into clinical practice to improve diagnostics, prognostic assessments, and personalized treatment strategies for UBC patients. Future research should focus on integrating multi- omics data and validating molecular biomarkers in large clinical trials to further enhance patient outcomes. 

Introduction.  Prostate cancer (PCa) is a common and relevant disease, especially in developed countries. Radical prostatectomy (RP) remains the gold standard for the treatment of localized PCa. However, research findings often show conflicting results regarding the potential dividends in patients that choose this option. A recent meta- analysis demonstrated that the greatest benefits were observed in the high-risk group of PCa patients. Therefore, the identification of this contingent of patients is highly relevant. 
Biomarkers remain promising in this context. In particular, PCA3, the use of which is actively discussed, taking into account the heterogeneity of the research results. In our opinion, this can be associated with the studies designs. Objectives. In this work, we tried to evaluate the relationship between the PCa patients urine PCA3 levels and the tumor dominant growth pattern (TDGP) according to the tumor zone origin (TZO) in the context of the postoperative ISUP class (ISUP-GG). Materials and methods. The inclusion criteria were the presence of results: urine PCA3, total PSA, prostate MRI, ISUP-GG. The study included 130 participants, that were divided into subgroups depending on the TZO and TDGP: aPCa (anterior), aPZ-PCa (anterior, peripheral zone) and pPZ-PCa (posterior, peripheral zone). Results. The zones of origin of tumors according to the division into subgroups determined on the basis of MRI were confirmed by the results of patho- histological conclusion.  A statistically significant difference between the study subgroups was observed only in PCA3 levels.  The PSA level was significantly different only between the aPZ-PCa and pPZ-PCa groups. Based on the results of Spearman's rank correlation analysis, a statistically significant positive relationship between the level of PCA3 and ISUP- GG was obtained in the pPZ-PCa group. Conclusions.  It is worth taking into account the TZO and TDGP of PCa when PCA3 urine levels is interpreted. 

Testicular cancer is the most common malignancy in young men, with early and accurate diagnosis being critical for effective management and prognosis. Traditionally, the diagnostic approach relies on scrotal ultrasound and serum tumor markers, which, while effective, have limitations in characterizing complex lesions and detecting small, non- palpable tumors or metastatic disease. Recent advancements in imaging technology have introduced multiparametric MRI (mpMRI) as a promising tool in the diagnostic armamentarium for testicular cancer. MpMRI combines multiple imaging sequences, including T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast- enhanced MRI (DCE-MRI), providing detailed anatomical and functional information about testicular lesions. This systematic review consolidates and evaluates current evidence regarding the role of mpMRI in the diagnosis, staging, and follow-up of testicular cancer. 
Key findings from the literature suggest that mpMRI offers superior sensitivity and specificity compared to conventional imaging techniques, particularly in distinguishing between benign and malignant lesions. It is also highly effective in the precise localization and staging of tumors, including the detection of small lymph node metastases, which are often missed by ultrasound or CT. This review highlights the potential of mpMRI to enhance diagnostic precision and influence treatment strategies in testicular cancer, while also identifying areas for further research, such as the optimization of imaging protocols and the assessment of mpMRI's impact on long-term clinical outcomes. The review underscores the importance of mpMRI as a non-invasive, highly informative imaging modality that could lead to more personalized and effective management of testicular cancer. 

Abstract

Androgen deprivation therapy (ADT) remains a cornerstone in the treatment of prostate cancer, but patient responses vary significantly. 
This systematic review evaluates the role and application of genomic and transcriptomic markers in assessing ADT efficacy and resistance. 
We analyzed 40 studies focusing on key markers such as AR-V7, TMPRSS2-ERG, RNA expression profiles, and the 23-gene signature. 
Our findings highlight the potential of these markers to personalize ADT, improve patient stratification, and guide treatment decisions. 
Despite promising results, challenges remain in standardization, cost, and clinical integration. 
Corresponding author. Mytsyk Yulian, Regional Specialist Hospital, Wroclaw, Poland, mytsyk.yulian@gmail.com 

Abstract
Background. Liver involvement secondary to multiple myeloma is a rare and uncommon radiologic finding.
Such extraosseous secondary lesions as well as tongue involvement require pathohistological confirmation to prevent misdiagnosis. Clinical and laboratory diagnostics are challenging in patients with COVID-19 and underlying multiple myeloma and its secondary lesions, leading to difficulties in treatment and outcomes.
Case Report. A 64-year-old male patient, not vaccinated against COVID-19, with a history of multiple myeloma presented with symptoms of headache, fatigue, dyspnea, cough, and fever. The patient’s medical history was intricate, involving cholecystectomy and a diagnosis of multiple myeloma, which was subsequently treated with chemotherapy and radiation therapy. Additionally, uncommon liver and tongue involvement secondary to multiple myeloma was found. Upon admission, the patient’s peripheral oxygen saturation was 90%, accompanied by increasing shortness of breath and a respiratory rate of 26 breaths per minute. A positive COVID-19 test was recorded. A lung computed tomography revealed bilateral multifocal areas of ground-glass opacity and consolidation, encompassing the entire pulmonary regions, corresponding to CO-RADS 6. The patient was admitted to the intensive care unit. Despite initiating oxygen support and symptomatic therapy, the patient’s death occurred. Autopsy confirmed the development of severe acute respiratory distress syndrome and bilateral hemorrhagic pneumonia, with multiple myeloma as a contributing factor.
Conclusions. This case report highlighted the rare occurrence of secondary liver involvement in multiple myeloma, characterized by nodules with distinct imaging features. It underscored the importance of identify- ing coexisting lesions, such as tongue involvement, and the diagnostic challenges they pose. Additionally, the case emphasized the need for comprehensive clinical assessment in patients with concurrent COVID-19 and underlying multiple myeloma, as it may lead to the development of acute respiratory distress syndrome.
Keywords
2019 Novel Coronavirus Disease; Multiple Myeloma; Liver Involvement; Acute Respiratory Distress Syn- drome; Computed Tomography; Diffuse Alveolar Damage